RECOTHROM Thrombin topical (Recombinant), manufactured using a recombinant technology, provides hospitals and their healthcare providers an innovative solution to address less severe intraoperative bleeding across multiple specialties to support natural healing.
See Indications
Recothrom Hero Image 2022

Recothrom Spray

The ONLY Recombinant Topical Thrombin1

Recombinant human thrombin was developed as an alternative with reduced immunogenicity and infectious risk.3

RECOTHROM is for topical use only – do not inject. You can learn how to reconstitute both configurations of RECOTHROM by downloading the preparation guide, below.

RECOTHROM Preparation

RECOTHROM is for topical use only – do not inject. You can learn how to reconstitute RECOTHROM by watching the preparation videos, below.

Versatility & Convenience

Child in a hospital bed
Indicated for Pediatric Use1

RECOTHROM is approved for use in both pediatric (≥1 month of age) and adult patients1

No Human or Animal Additives1

The cell culture process used in the manufacturing of RECOTHROM employs no additives of human or animal origin1

Long-Lasting Stability1

RECOTHROM is stable at room temperature for 24 hours following reconstitution1

Recothrom vs Bovine Thrombin Chart

Clinically Proven1

95% of patients treated with RECOTHROM achieved hemostasis within 10 minutes, comparable to bovine thrombin in a non-inferiority study.1,2

In clinical trials, RECOTHROM has been used in patients with or without preexisting bovine or recombinant human thrombin antibodies.1

Additional Product Benefits

Low Antiproduct Antibody Formation

A phase 3 study showed that 1.5% of patients receiving RECOTHROM developed antiproduct antibodies, compared with 21.5% of patients receiving bovine thrombin.1,2*


*This study was not designed or powered to detect an association between antibody formation and adverse clinical outcomes. The overall incidence of AE’s was similar between treatment groups.

Versatile Surgical Applications

Proven efficacy across broad surgical specialties. RECOTHROM may be applied with absorbable gelatin sponge (USP), spray pump, or syringe-tip sprayer.1

A Variety of Configurations

RECOTHROM is available in two sizes: 5,000 units and 20,000 units. An additional spray configuration is available in 20,000 units.1


RECOTHROM Thrombin topical (Recombinant) Indication

RECOTHROM Thrombin topical (Recombinant) is a topical thrombin indicated to aid hemostasis whenever oozing blood and minor bleeding from capillaries and small venules is accessible and control of bleeding by standard surgical techniques (such as suture, ligature, or cautery) is ineffective or impractical in adults and pediatric populations greater than or equal to one month of age.

RECOTHROM may be used in conjunction with an absorbable gelatin sponge, USP.



  • Do not inject directly into the circulatory system.
  • Do not use for the treatment of massive or brisk arterial bleeding.
  • Do not administer to patients with a history of hypersensitivity to RECOTHROM or any components of RECOTHROM.
  • Do not use in patients with known hypersensitivity to hamster proteins.

Warnings and Precautions

  • RECOTHROM may cause thrombosis if it enters the circulatory system. Apply topically. DO NOT INJECT.
  • Hypersensitivity reactions, including anaphylaxis, may occur. RECOTHROM is produced in a genetically modified Chinese Hamster Ovary (CHO) cell line and may contain hamster or snake proteins.

Adverse Reactions

  • Thromboembolic adverse reactions were reported in 6% of surgical patients treated with RECOTHROM in all completed clinical trials (N=644).
  • Antibody formation to RECOTHROM occurred in <1% of patients. None of the antibodies detected neutralized native human thrombin.

Use in Specific Populations

  • Pregnancy: Animal reproduction studies have not been conducted with RECOTHROM thrombin. It is also not known whether RECOTHROM can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. RECOTHROM should be given to a pregnant woman only if clearly needed.
  • Pediatric Use: Safety and efficacy have not been established in neonates.
  • Geriatric Use: Of 644 patients in clinical studies of RECOTHROM, 36% (n=232/644) were ≥65 years old and 15% (n=95/644) were ≥75 years old. No differences in safety or effectiveness were observed between these patients and younger patients, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

Please see accompanying full Prescribing Information